<DOC>
	<DOCNO>NCT00036816</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell decrease recurrence melanoma eye . PURPOSE : Randomized phase III trial determine effectiveness vaccine therapy treat patient high risk recurrent melanoma eye .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Melanoma Eye</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether adjuvant NA17-A melanoma differentiation peptide effective decrease occurrence liver metastasis HLA-A2-positive patient primary ocular melanoma high risk relapse . - Determine whether regimen increase survival patient . - Determine toxicity regimen patient . OUTLINE : This randomize , multicenter study . Patients stratify accord tumor size ( medium vs large ) , prior treatment primary tumor ( surgery v radiotherapy ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive vaccination NA17-A melanoma differentiation peptide ( e.g. , tyrosinase , Melan-A , gp100 antigen ) subcutaneously intradermally day 1 , 8 , 15 , 22 . Patients receive vaccination every 14 day 4 dos , every 28 day 4 dos , every 56 day 4 dos , every 3 month total 4 year . - Arm II : Patients undergo observation every 3 month 2 year every 6 month 2 year . All patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 600 patient ( 300 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ocular melanoma No melanoma iris Disease adequately treat prior surgery ( enucleation tumorectomy ) and/or radiotherapy No 5 week since begin primary tumor treatment Measurable disease At least 12.0 mm large diameter OR At least 6.0 mm height HLAA2 positive No distant metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Hemoglobin least 9 g/dL Neutrophil count least 2,000/mm^3 Lymphocyte count least 700/mm^3 Platelet count least 100,000/mm^3 No bleed disorder Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Lactate dehydrogenase great 2 time ULN Alkaline phosphatase great 2 time ULN Gamma glutamyl transpeptidases great 2 time ULN Hepatitis C antibody negative Hepatitis B antigen negative Renal : Creatinine great 2.0 mg/dL Immunologic : No clinical immunodeficiency No autoimmune diseases No inflammatory bowel disease No active infection require antibiotic No multiple sclerosis Other : HIV negative No malignancy except surgically cure carcinoma situ cervix basal cell squamous cell carcinoma skin No uncontrolled illness No psychological , familial , sociological , geographical condition would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy biologic therapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : At least 3 week since prior steroid No concurrent chronic therapy high dos corticosteroid ( e.g. , methylprednisolone least 12 mg/day ) Concurrent topical inhalation steroid allow No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Prior proton beam therapy allow Prior brachytherapy without tumor resection allow Recovered prior radiotherapy No prior radiotherapy spleen No prior preenucleation radiotherapy No prior ruthenium Ru 106 primary therapy alone No concurrent radiotherapy Surgery : See Disease Characteristics Prior transcleral tumor resection allow Recovered prior surgery No prior major organ allograft No prior splenectomy Other : No concurrent investigational drug No concurrent systemic immunosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
</DOC>